We previously demonstrated on a panel of human colorectal cancer cell lines that cetuximab can enhance the antitumour activity of oxaliplatin and the observed responses were strictly dependent on the cell type, not correlated with the level of EGFR expression but related to the basal level of phospho-EGFR. This evidence concerns the gene EGFR and colorectal cancer.